Angela Coxon,James Bready,Hosung Min,Stephen Kaufman,Juan Leal,Dongyin Yu,Tani Ann Lee,Ji-Rong Sun,Juan Estrada,Brad Bolon,James McCabe,Ling Wang,Karen Rex,Sean Caenepeel,Paul Hughes,David Cordover,Haejin Kim,Seog Joon Han,Mark L. Michaels,Eric Hsu,Grant Shimamoto,Russell Cattley,Eunju Hurh,Linh Nguyen,Shao Xiong Wang,Anthony Ndifor,Isaac J. Hayward,Beverly L. Falcon,Donald M. McDonald,Luke Li,Tom Boone,Richard Kendall,Robert Radinsky,Jonathan D. Oliner

Abstract:AbstractAMG 386 is an investigational first-in-class peptide-Fc fusion protein (peptibody) that inhibits angiogenesis by preventing the interaction of angiopoietin-1 (Ang1) and Ang2 with their receptor, Tie2. Although the therapeutic value of blocking Ang2 has been shown in several models of tumorigenesis and angiogenesis, the potential benefit of Ang1 antagonism is less clear. To investigate the consequences of Ang1 neutralization, we have developed potent and selective peptibodies that inhibit the interaction between Ang1 and its receptor, Tie2. Although selective Ang1 antagonism has no independent effect in models of angiogenesis-associated diseases (cancer and diabetic retinopathy), it induces ovarian atrophy in normal juvenile rats and inhibits ovarian follicular angiogenesis in a hormone-induced ovulation model. Surprisingly, the activity of Ang1 inhibitors seems to be unmasked in some disease models when combined with Ang2 inhibitors, even in the context of concurrent vascular endothelial growth factor inhibition. Dual inhibition of Ang1 and Ang2 using AMG 386 or a combination of Ang1- and Ang2-selective peptibodies cooperatively suppresses tumor xenograft growth and ovarian follicular angiogenesis; however, Ang1 inhibition fails to augment the suppressive effect of Ang2 inhibition on tumor endothelial cell proliferation, corneal angiogenesis, and oxygen-induced retinal angiogenesis. In no case was Ang1 inhibition shown to (a) confer superior activity to Ang2 inhibition or dual Ang1/2 inhibition or (b) antagonize the efficacy of Ang2 inhibition. These results imply that Ang1 plays a context-dependent role in promoting postnatal angiogenesis and that dual Ang1/2 inhibition is superior to selective Ang2 inhibition for suppression of angiogenesis in some postnatal settings. Mol Cancer Ther; 9(10); 2641–51. ©2010 AACR.

Supplementary Figures 1-2 from Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth

Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Supplementary Figure Legends 1-2 from Angiopoietin-1 Overexpression Modulates Vascular Endothelium to Facilitate Tumor Cell Dissemination and Metastasis Establishment

Supplementary Figures 1-4 from Angiocrine Factors Modulate Tumor Proliferation and Motility through EphA2 Repression of Slit2 Tumor Suppressor Function in Endothelium

Supplementary Figures from the Amino-Terminal Oligomerization Domain of Angiopoietin-2 Affects Vascular Remodeling, Mammary Gland Tumor Growth, and Lung Metastasis in Mice

Supplementary Data from SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth in Vivo

Supplementary Figure 2 from Vasculostatin Inhibits Intracranial Glioma Growth and Negatively Regulates <i>in Vivo</i> Angiogenesis Through a CD36-Dependent Mechanism

Data from Angiopoietin-1 Overexpression Modulates Vascular Endothelium to Facilitate Tumor Cell Dissemination and Metastasis Establishment

Supplementary Figure 2 from RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma

Expression and Significance of Angiopoietin-2 in Gastric Cancer.

Supplementary Figure 2 from Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

Supplementary Figure Legends 1-9 from Overexpression of Platelet-Derived Growth Factor-BB Increases Tumor Pericyte Content Via Stromal-Derived Factor-1α/CXCR4 Axis

Expression of Angiopoietin-2 is Correlated with Vascularization and Tumor Size in Human Colorectal Adenocarcinoma.

Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization

Data from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody

MicroRNA‐542‐3p Inhibits Tumour Angiogenesis by Targeting Angiopoietin‐2

Supplementary Figure 1 from Activating Peroxisome Proliferator-Activated Receptor Γ Mutant Promotes Tumor Growth in Vivo by Enhancing Angiogenesis

Supplementary Figure 4 from Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

Angiopoietin-2 inhibits the growth of tongue carcinoma without affecting expression of vascular endothelial growth factor